年代秀

Dhurandhar Box Office Day 4: Ranveer Singh's Film Sees a Dip in Collection_我的网站

冒险岛2

一 |     After showing growth over the weekend, Ranveer Singh and Aditya Dhar's Dhurandhar faced its first Monday test at the box office. The spy-thriller that released theatrically on December 5, sees Singh as an Indian spy who infiltrates a terror base in Pakistan. It also features an ensemble cast of Arjun Rampal, Akshaye Khanna, Sara Arjun, Sanjay Dutt, Rakesh Bedi and R Madhavan, among others.     The collections saw a dip on its first Monday. As per early estimates by Sacnilk, the film earned around Rs 23 crore, which is around 46% less than the amount it minted on the day it released.          On its opening day, Dhurandhar earned Rs 28 crore, followed by Rs 32 crore and Rs 43 crore on Saturday and Sunday respectively. On Monday, December 8, it had an overall Hindi occupancy of 32.43%. The total collection in India now stands at around Rs 126 crore. The film entered the Rs 100 crore club on day 3 of its release.     Filmfare rated the film 3.5 out of 5 and said in its review, "At the centre of this world stands Ranveer Singh, playing the hard-edged agent who slips into the shadow world of sleeper operatives as a cross-border conspiracy erupts. It’s a performance of restraint, a departure from his flamboyant screen persona. This Ranveer is raw yet internalised, driven yet fraying. The role demands both physical ferocity and emotional weariness, and he delivers both with remarkable control. His silences speak as loudly as his action beats, grounding the film even when its narrative ambitions begin to overtake its focus."          Dhurandhar's sequel, the continuation of the story through a Part 2 feature, will be released in March next year. Fans are eagerly waiting to see how the story unfolds next.Also Read: Inside Dhurandhar: How Smriti Chauhan Crafted Ranveer Singh’s Most Talked-about Look – Exclusive。    

【国际战“疫”行动】科技日报讯 （记者张梦然）以色列科学家在新冠病毒抗体研究中取得突破。新研究证明，从康复的新冠患者免疫系统中分离出的两种抗体可有效中和所有已知的新冠毒株，包括德尔塔和奥密克戎变种，其最高中和有效性高达97%。这一发现可能会消除重复加强疫苗接种的需要，并增强高危人群的免疫能力。该研究发表在最近的《自然》杂志子刊《通讯生物学》上。

二 | 本研究是2020年10月在新冠疫情最严重时进行的初步研究的延续。特拉维夫大学娜塔莉亚·弗洛恩德博士团队对从原始新冠毒株中恢复的以色列患者血液中的所有B免疫系统细胞进行了测序，并分离了患者产生的9种抗体。研究人员发现，其中一些抗体在中和新的冠状病毒变种（德尔塔和奥密克戎）方面非常有效。新研究证明，其中两种抗体TAU-1109和TAU-2310，与病毒刺突蛋白结合的区域与迄今为止大多数抗体集中的区域不同，在中和德尔塔和奥密克戎变种方面非常有效。

三 | 根据研究结果，第一种抗体TAU-1109中和奥密克戎变种的有效性为92%，中和德尔塔变种的有效性为90%；第二种抗体TAU-2310中和奥密克戎变种的有效性为84%，中和德尔塔变种的有效性为97%。研究人员解释说，这些抗体的惊人功效可能与病毒的进化有关：病毒的传染性随着每个变种的增加而增加，因为每一次，它都会改变刺突蛋白部分的氨基酸序列，与ACE2受体结合，从而增加其传染性，同时避开疫苗接种后产生的天然抗体。

四 | 相比之下，抗体TAU-1109和TAU-2310不与ACE2受体结合位点结合，而是与刺突蛋白的另一个区域结合，这是一个由于某种原因不会发生很多突变的病毒刺突区域，因此它们可有效中和更多的病毒变种。

五 | 这些是研究人员在测试了迄今为止所有已知的新冠毒株后发现的。

六 | 弗洛恩德博士认为，抗体可在对抗新冠病毒的斗争中带来真正的革命：用抗体进行靶向治疗并将其以高浓度输送到体内，可作为重复加强免疫的有效替代品，特别是对于高危人群和免疫系统较弱的人群。新冠病毒感染会导致严重的疾病，在感染后的最初几天提供抗体可阻止病毒的传播。因此，通过有效的抗体治疗，可能不必在每次出现新变种时让整个人群接种加强疫苗。

Current article:http://xkzi7.dingruorenhongqiaminmeipeiliu.cyou/1q4t7k/20260826/392914.html

Published on:14:06:50